


Selatogrel

Cat. No.:	HY-109122
CAS No.:	1159500-34-1
Molecular Formula:	C ₂₈ H ₃₉ N ₆ O ₈ P
Molecular Weight:	618.62
Target:	P2Y Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Selatogrel (ACT-246475) is a reversible and selective P2Y ₁₂ receptor antagonist which inhibits platelet aggregation with an IC ₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy ^[1] .								
In Vivo	<p>Selatogrel (0-0.1 mg/kg, i.v., single dosage) dose-dependently blocks thrombus formation in the wistar rat FeCl₃ model and causes less surgical blood loss^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>FeCl₃ induced arterial injury in wistar rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0-0.1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v., 5 minutes before arterial injury</td> </tr> <tr> <td>Result:</td> <td>Prevented the FeCl₃-induced thrombotic occlusions in a dose-dependent manner with minimal observed surgical blood loss of 0.4 g.</td> </tr> </table>	Animal Model:	FeCl ₃ induced arterial injury in wistar rats ^[1]	Dosage:	0-0.1 mg/kg	Administration:	i.v., 5 minutes before arterial injury	Result:	Prevented the FeCl ₃ -induced thrombotic occlusions in a dose-dependent manner with minimal observed surgical blood loss of 0.4 g.
Animal Model:	FeCl ₃ induced arterial injury in wistar rats ^[1]								
Dosage:	0-0.1 mg/kg								
Administration:	i.v., 5 minutes before arterial injury								
Result:	Prevented the FeCl ₃ -induced thrombotic occlusions in a dose-dependent manner with minimal observed surgical blood loss of 0.4 g.								

REFERENCES

[1]. Caroff E, et al., 4-((R)-2-[[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino]-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y₁₂ Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. J Med Chem. 2015 Dec 10;58(23):9133-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA